Get the Stockscreener App
5.03
5.09%
-0.27
After Hours:
5.00
-0.03
-0.60%
Achieve Life Sciences Inc stock is traded at $5.03, with a volume of 855.16K.
It is down -5.09% in the last 24 hours and up +14.84% over the past month.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.
See More
Previous Close:
$5.30
Open:
$5.3
24h Volume:
855.16K
Relative Volume:
0.69
Market Cap:
$516.38M
Revenue:
-
Net Income/Loss:
$-54.65M
P/E Ratio:
-3.8848
EPS:
-1.2948
Net Cash Flow:
$-49.47M
1W Performance:
+10.31%
1M Performance:
+14.84%
6M Performance:
+10.55%
1Y Performance:
+28.97%
1-Day Range:
$5.03
$5.30
1-Week Range:
$4.48
$5.53
52-Week Range:
$2.00
$6.15
Achieve Life Sciences Inc Stock (ACHV) Company Profile
Name
Achieve Life Sciences Inc
Sector
Industry
Phone
425-686-1500
Address
22722 29TH DR. SE, SEATTLE, BC
Compare ACHV vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACHV
Achieve Life Sciences Inc
|
5.03 | 544.09M | 0 | -54.65M | -49.47M | -1.2948 |
VRTX
Vertex Pharmaceuticals Inc
|
425.09 | 111.27B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
602.92 | 62.97B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
802.17 | 51.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.12 | 39.47B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.31 | 34.80B | 742.00K | -1.37B | -1.07B | -7.0731 |
Achieve Life Sciences Inc Stock (ACHV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Buy |
| Nov-25-25 | Initiated | Citizens JMP | Mkt Outperform |
| Aug-21-25 | Initiated | H.C. Wainwright | Buy |
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
| Sep-27-24 | Initiated | Raymond James | Strong Buy |
| May-10-23 | Reiterated | Maxim Group | Buy |
| Jun-23-21 | Initiated | Oppenheimer | Outperform |
View All
Achieve Life Sciences Inc Stock (ACHV) Latest News
Achieve Life Sciences (ACHV) director awarded 47,250 options at $5.24 strike - Stock Titan
Achieve Life (ACHV) director receives 47,250 options at $5.24 strike - Stock Titan
ACHIEVE Life Sciences (ACHV) director reports no beneficial ownership on Form 3 - Stock Titan
Achieve Life Sciences (ACHV) director Farrow files Form 3 with no share ownership - Stock Titan
Achieve Life Sciences, Inc. Announces Board Appointments - marketscreener.com
Achieve Life Sciences, Inc. Files Form 8-K Current Report with SEC on May 29, 2026 - Minichart
Achieve Life Sciences appoints two new directors to board and committees - Investing.com
Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors - The Globe and Mail
[8-K] ACHIEVE LIFE SCIENCES, INC. Reports Material Event - Stock Titan
Achieve Life Sciences (ACHV) asks shareholders to double authorized common shares to 300M - Stock Titan
Achieve Life Sciences 4Q Loss/Shr 28c >ACHV - Moomoo
Achieve Life Sciences Completes Tech Transfer to Adare Pharma Solutions - Contract Pharma
[EFFECT] ACHIEVE LIFE SCIENCES, INC. SEC Filing - Stock Titan
Achieve Life Sciences Q1 2026 Earnings: Narrower-than-Expected Loss Drives OptimismEnergy Earnings Report - thelegaladvocate.com
Canaccord reiterates Achieve Life Sciences stock rating on safety data By Investing.com - Investing.com South Africa
Achieve Life Sciences (ACHV) price target decreased by 14.04% to 12.82 - MSN
Canaccord reiterates Achieve Life Sciences stock rating on safety data - Investing.com
Q3 2025 Achieve Life Sciences Inc Earnings Call Transcript - GuruFocus
Achieve Life Sciences presents long-term cytisinicline data By Investing.com - Investing.com Australia
Achieve Life Sciences presents long-term cytisinicline data - Investing.com UK
Achieve Life Sciences, Inc.: cytisinicline data indicate well-tolerated safety over 52 weeks for adults quitting smoking - Traders Union
Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment - The Manila Times
Achieve Life Sciences Presents Long-Term Safety Data for Cytisinicline in Smoking Cessation at ATS 2026 - Quiver Quantitative
Achieve Life Sciences Presents Safety Data From 52 Weeks of Continuous Cytisinicline Treatment - 富途牛牛
ACHV Technical Analysis | Trend, Signals & Chart Patterns | ACHIEVE LIFE SCIENCES INC (NASDAQ:ACHV) - ChartMill
Achieve Life Sciences Q1 earnings call highlights - MSN
Achieve (ACHV) Q1 2026 Earnings Transcript - AOL.com
Q2 Earnings Forecast for ACHV Issued By Zacks Research - MarketBeat
Canaccord Genuity initiates coverage of Achieve Life Sciences (ACHV) with buy recommendation - MSN
Earnings call transcript: Achieve Life Sciences beats Q1 2026 EPS expectations - Investing.com
HC Wainwright Has Optimistic Outlook of ACHV Q2 Earnings - MarketBeat
[Form 3] ACHIEVE LIFE SCIENCES, INC. Initial Statement of Beneficial Ownership - Stock Titan
Director at ACHIEVE Life Sciences (ACHV) granted 47,250 stock options at $5.59 - Stock Titan
Achieve Life Sciences: 'Hold' On Expected CRL Cytisinicline And Q4 2026 NDA Resubmission - Seeking Alpha
Achieve Life Sciences, Inc.Common Shares (NQ: ACHV - FinancialContent
Achieve Life Sciences, Inc. (NASDAQ:ACHV) Q1 2026 Earnings Call Transcript - Insider Monkey
Achieve Life Sciences (ACHV) registers 99.04M shares for resale by investors - Stock Titan
Achieve Life Sciences Releases Q1 2026 Financial Results - AlphaStreet
Achieve Life Sciences (ACHV) Secures $180M Financing for Cytisin - GuruFocus
Achieve Life Sciences, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Earnings call transcript: Achieve Life Sciences Q1 2026 beats EPS expectations - Investing.com
Achieve Life Sciences Q1 2026: Loss Narrows 38.7% to -$0.19/Share - AlphaStreet
Achieve Life Sciences Q1 Earnings Call Highlights - MarketBeat
Achieve Life Sciences adds three executives to leadership team By Investing.com - Investing.com South Africa
ACHV: Achieve Aims for FDA Approval of Cytisinicline as New Smok - GuruFocus
How Should Investors Value Achieve Life Sciences (ACHV) After Q1 - GuruFocus
Achieve Life Sciences Inc Stock (ACHV) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):